Scholarlink

Background <p>Radiotherapy (RT) is a cornerstone in cancer management, but late radiation tissue injury (LRTI) remains a relevant clinical issue, affecting approximately 5% of patients and significantly impacting quality of life. Hyperbaric oxygen therapy (HBOT), by enhancing tissue oxygenation and promoting neovascularization, has been proposed both as a treatment for RT-induced toxicities and as a potential radiosensitizer. However, available evidence is heterogeneous and often limited by small cohorts.</p> Methods <p>A systematic review of PubMed, Embase, and Cochrane databases was conducted in September 2025. Eligible studies, published between 2000 and 2025, evaluated HBOT in patients receiving RT. Exclusion criteria included reviews, case reports with &lt; 4 patients, and non-English publications. Data extraction included study design, patient and treatment characteristics, HBOT parameters, outcomes, and toxicity.</p> Results <p>Forty-two studies (2785 patients) were included, of which 28 were retrospective and 5 randomized controlled trials. Median age was 59 years; most patients were female. HBOT was primarily applied for toxicity management, with a median of 34.5 sessions at 2.45 atm. The pelvic district accounted for the largest patient cohort, with HBOT yielding high response rates (67–100%) for hemorrhagic cystitis. In breast and head-neck cancer, HBOT improved quality of life and toxicity profiles in retrospective reports, but randomized trials failed to demonstrate consistent benefit. Limited data suggested potential benefit in preventing cerebral radionecrosis and a speculative radiosensitizing role in gliomas. HBOT was overall safe, with mild adverse events such as barotrauma and transient myopia.</p> Conclusions <p>HBOT shows promising activity in mitigating late RT toxicities, particularly in pelvic toxicities, while evidence in other anatomical sites remains conflicting. Its hypothesized radiosensitizing role is largely speculative. Given the heterogeneity and low evidence level of existing studies, well-designed prospective trials are needed to clarify patient selection, optimal HBOT parameters, and its potential integration with RT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Between hope and uncertainty: the elusive evidence on hyperbaric oxygen therapy and radiotherapy

  • 期刊论文

  • 发表日期：

    2026年2月2日

查看全文
  • Francesco Cuccia,
  • Andrea Neville Cracchiolo,
  • Antonio Piras,
  • Salvatore D’Alessandro,
  • Giuseppe Carruba,
  • Sebastiano Mercadante,
  • Giuseppe Ferrera

摘要

Background

Radiotherapy (RT) is a cornerstone in cancer management, but late radiation tissue injury (LRTI) remains a relevant clinical issue, affecting approximately 5% of patients and significantly impacting quality of life. Hyperbaric oxygen therapy (HBOT), by enhancing tissue oxygenation and promoting neovascularization, has been proposed both as a treatment for RT-induced toxicities and as a potential radiosensitizer. However, available evidence is heterogeneous and often limited by small cohorts.

Methods

A systematic review of PubMed, Embase, and Cochrane databases was conducted in September 2025. Eligible studies, published between 2000 and 2025, evaluated HBOT in patients receiving RT. Exclusion criteria included reviews, case reports with < 4 patients, and non-English publications. Data extraction included study design, patient and treatment characteristics, HBOT parameters, outcomes, and toxicity.

Results

Forty-two studies (2785 patients) were included, of which 28 were retrospective and 5 randomized controlled trials. Median age was 59 years; most patients were female. HBOT was primarily applied for toxicity management, with a median of 34.5 sessions at 2.45 atm. The pelvic district accounted for the largest patient cohort, with HBOT yielding high response rates (67–100%) for hemorrhagic cystitis. In breast and head-neck cancer, HBOT improved quality of life and toxicity profiles in retrospective reports, but randomized trials failed to demonstrate consistent benefit. Limited data suggested potential benefit in preventing cerebral radionecrosis and a speculative radiosensitizing role in gliomas. HBOT was overall safe, with mild adverse events such as barotrauma and transient myopia.

Conclusions

HBOT shows promising activity in mitigating late RT toxicities, particularly in pelvic toxicities, while evidence in other anatomical sites remains conflicting. Its hypothesized radiosensitizing role is largely speculative. Given the heterogeneity and low evidence level of existing studies, well-designed prospective trials are needed to clarify patient selection, optimal HBOT parameters, and its potential integration with RT.